Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

25%

1 of 4 completed trials have results

Key Signals

2 recruiting1 with results

Enrollment Performance

Analytics

Phase 2

5(71.4%)

Phase 3

1(14.3%)

Phase 1

1(14.3%)

7Total

Phase 2(5)

Phase 3(1)

Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT07298005Phase 2Recruiting

Sonlicromanol in Post-COVID

Role: collaborator

NCT06451757Phase 3Recruiting

KHENERFIN Study: A Trial to Evaluate the Efficacy and Safety of Sonlicromanol in Primary Mitochondrial Diseases

Role: lead

NCT04846036Phase 2Suspended

The KHENERGYC Study

Role: lead

NCT04604548Phase 2Completed

The KHENEREXT Study

Role: lead

NCT04165239Phase 2Completed

The KHENERGYZE Study

Role: lead

NCT02544217Phase 1Completed

A Dose-escalating Clinical Trial With KH176

Role: lead

NCT02909400Phase 2Completed

The KHENERGY Study

Role: lead

All 7 trials loaded